Moonshots with Peter Diamandis

Podbit · Moonshots with Peter Diamandis

The AI Duopoly Is Over: Grok 4. 5 , GPT-5 . 6 , and Muse Spark in One Week | #270

Explore episode Jul 13, 2026
Science
China Lands Its First Orbital Booster — The Heavy Launch Monopoly Is Ending

The AI Duopoly Is Over: Grok 4. 5 , GPT-5 . 6 , and Muse Sp… · Jul 13, 2026 Science

China just demonstrated the propulsive landing of an orbital booster for the first time — a milestone SpaceX reached years ago but that no other nation had managed. Against SpaceX's 580 total reflights and a single booster flown 36 times, China is years behind. But the monopoly on reusable heavy launch is now cracking.

Where this was said

Starship Flight 13, Starlink V3, and Very Low Earth Orbit Satellites

At 48:20 · chapter starts 44:50

Peter reports that SpaceX has filed for 100,000 low-Earth orbit Starlink V3 spacecraft — up from the current 10,700 V2 satellites — with each V3 designed to support billions of AI-powered devices at multi-gigabit symmetrical throughput and extremely low latency. Starship Flight 13 is imminent, with Starship V3 booster and ship being tested. Dave Blundin, reflecting on recent podcast conversations with Will Marshall and Philip Johnston, argues that low Earth orbit is a scarce, self-cleaning resource — small objects are hit by solar wind, enter elliptical orbits, and eventually incinerate in the atmosphere. The US's infamous decision to launch 100,000 needles into orbit for radio reflection experiments took until 2026 to fully self-clean. Alex Wissner-Gross introduces the concept of very low Earth orbit (VLEO) satellites — so low they taste the atmosphere — which would look more like high-altitude balloons operating at orbital velocities, potentially air-breathing designs that could be kept aloft cheaply with periodic boosts.

Similar podbits

Science
The Placebo Effect Is Not Fake — It Just Belongs to the Story, Not the Drug

#403 ‒ Peptides: separating scientific promise from marketi… · Aug 10, 2026 Science

Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.